Innate immune mechanisms and immunotherapy of myeloid malignancies

Sara Small; Yazan Numan; Leonidas C. Platanias

doi:10.3390/biomedicines9111631

Innate immune mechanisms and immunotherapy of myeloid malignancies

Sara Small, Yazan Numan, Leonidas C. Platanias

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.

Original language	English
Article number	1631
Journal	Biomedicines
Volume	9
Issue number	11
DOIs	https://doi.org/10.3390/biomedicines9111631
State	Published - Nov 2021
Externally published	Yes

Keywords

AML
Antibodies
CAR-T
Interferon
Myeloid malignancies
immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/biomedicines9111631

Cite this

@article{81985c64d57847d49e32e4bcc37d578d,

title = "Innate immune mechanisms and immunotherapy of myeloid malignancies",

abstract = "Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.",

keywords = "AML, Antibodies, CAR-T, Interferon, Myeloid malignancies, immunotherapy",

author = "Sara Small and Yazan Numan and Platanias, {Leonidas C.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

doi = "10.3390/biomedicines9111631",

language = "English",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "11",

}

TY - JOUR

T1 - Innate immune mechanisms and immunotherapy of myeloid malignancies

AU - Small, Sara

AU - Numan, Yazan

AU - Platanias, Leonidas C.

PY - 2021/11

Y1 - 2021/11

N2 - Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.

AB - Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.

KW - AML

KW - Antibodies

KW - CAR-T

KW - Interferon

KW - Myeloid malignancies

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85119627933&partnerID=8YFLogxK

U2 - 10.3390/biomedicines9111631

DO - 10.3390/biomedicines9111631

M3 - Review article

AN - SCOPUS:85119627933

SN - 2227-9059

VL - 9

JO - Biomedicines

JF - Biomedicines

IS - 11

M1 - 1631

ER -

Innate immune mechanisms and immunotherapy of myeloid malignancies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this